Hannah Kerr-Peterson

Hannah Kerr-Peterson

Associate
London

Email hannah.kerr-peterson@​hoganlovells.com

Phone +44 20 7296 2867

Fax +44 20 7296 2001

LanguagesEnglish

Practice groupGlobal Regulatory

Hannah Kerr-Peterson is a life sciences regulatory lawyer in our London office. She advises clients in relation to the regulation of pharmaceutical, medical device, and digital health technologies in the United Kingdom and at the European Union (EU) level, particularly in relation to product classification, clinical research, authorization, manufacturing, distribution, advertising, labelling and pricing, and reimbursement.

Hannah has been involved in litigation before the national and EU courts, including challenges on behalf of industry clients, to decisions of the UK licensing authority and the European Medicines Agency. Hannah also works with clients to resolve disputes with entities such as NHS England, the Medicines and Healthcare products Regulatory Agency, and the Prescription Medicines Code of Practice Authority.

Hannah also advises on commercial contracts within the sector including those related to clinical trials, consultancy, health care professional sponsorship, joint working services, and pharmacovigilance.

Prior to joining the firm, Hannah trained and worked at the London office of a U.S. firm. During that time, she completed two client secondments, one to the UK affiliate of a multinational pharmaceutical company during the implementation of the General Data Protection Regulation, and one to the head office of a major European aircraft manufacturer where she assisted the regulatory litigation team.

Education and admissions

Education

Legal Practice Course, The University of Law, 2015

Graduate Diploma in Law, BPP University Law School, 2013

Pharmacology and Molecular Genetics, Bachelor of Science (with Honors), King's College London, 2012

Bar admissions and qualifications

Solicitor, England and Wales

Representative experience

Acting for a pharmaceutical company in its challenge of a European Commission decision to grant a marketing authorization without orphan designation.

Acting for a multinational pharmaceutical company in its provision of information to, and cooperation with, the Infected Blood Inquiry.

Advising a healthcare provider on the rules regarding the delivery of telemedicine services.

Advising a number of pharmaceutical and biotechnology companies on how to prepare for Brexit.

Acting for a multinational pharmaceutical company in an advanced-stage Prescription Medicines Code of Practice Authority complaint.

Advising various companies on compliance with EU and UK regulations on CBD including in medical devices, food supplements and personal care products.

Acting for senior executives of a pharmaceutical company in a SFO investigation concerning allegations of bribery and corruption.

Advising a company on regulatory compliance issues for the launch of its nutrition product, including labelling and claims.

Loading data